A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

Saved in:

書目詳細資料
Main Authors:	Giorgio V. Scagliotti, Denis Moro‐Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te‐Chun Hsia, Matteo Brighenti, Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaron M. Gruver, Johan Wallin, Kambiz Mansouri, Volker Wacheck, Gee‐Chen Chang
格式:	Artigo
語言:	英语
出版:	2019
在線閱讀:	https://doi.org/10.1016/j.jtho.2019.10.003 http://www.jto.org/article/S1556086419335300/pdf
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

因特網